logo-loader
viewOpen Orphan PLC

Venn Life Sciences CEO focused on sizable deals

Venn Life Sciences (LON:VENN) chief executive Tony Richardson says the biotech services company is focused on brining larger deals into its pipeline.

“We’re now frequently bidding for contracts worth £1mln-2mln in value, which is a step up from where we were 18 months ago,” said Richardson.

The firm told investors today that it expects revenues for the full year 2015 to be at least double the prior year, in which it had €4.9mln.

Quick facts: Open Orphan PLC

Price: 14.7 GBX

AIM:ORPH
Market: AIM
Market Cap: £87.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Innovenn split will ‘maximise shareholder value’, says Venn CEO

Venn Life Sciences Holdings plc (LON:VENN) chief executive Tony Richardson says that separating Innovenn from its core business simplifies the firm and generates more value for shareholders. Speaking exclusively to Proactive, Richardson says: “Spinning [Innovenn] out, we believe, will...

on 5/10/16

2 min read